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Abstract
 
Signaling through its widely distributed cell surface receptor, interleukin (IL)-17 enhances the
transcription of genes encoding proinflammatory molecules. Although it has been well docu-
 
mented that IL-17 activates the transcription factor nuclear factor (NF)-
 
k
 
B and c-Jun NH
 
2
 
-
terminal kinase (JNK), the upstream signaling events are largely unknown. Here we report the
requirement of tumor necrosis factor receptor–associated factor (TRAF)6 in IL-17–induced
NF-
 
k
 
B and JNK activation. In embryonic fibroblasts (EFs) derived from TRAF6 knockout
mice, IL-17 failed to activate the I
 
k
 
B kinases (IKKs) and JNK. Consequently, IL-17–induced
IL-6 and intercellular adhesion molecule 1 expression in the TRAF6-deficient cells was abol-
ished. Lack of TRAF6 appeared to be the sole defect responsible for the observed failure to
respond to IL-17, because transient transfection of TRAF6 expression plasmid into the
TRAF6-deficient cells restored IL-17–induced NF-
 
k
 
B activation in a luciferase reporter as-
say. Furthermore, the levels of IL-17 receptor (IL-17R) on the TRAF6-deficient EFs were
comparable to those on the wild-type control cells. Defect in IL-17 response was not ob-
served in TRAF2-deficient EFs. Moreover, when TRAF6 and IL-17R were coexpressed in
293 cells, TRAF6 coimmunoprecipitated with IL-17R. Together, these results indicate that
TRAF6, but not TRAF2, is a crucial component in the IL-17 signaling pathway leading to
proinflammatory responses.
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Introduction
 
IL-17, previously termed CTLA-8 (cytotoxic T cell lym-
phocyte–associated antigen 8; reference 1), is a 20–30-kD
protein secreted by activated CD4 cells, mainly Th0 and
Th1 cells (2, 3). In different cell types, IL-17 induces the
expression of a large variety of proinflammatory molecules,
 
including IL-1
 
b
 
, IL-8, inducible nitric oxide synthase,
cyclooxigenase-2, and intercellular adhesion molecule
(ICAM)-1 (3–6). IL-17 also reportedly induces hematopoi-
etic cytokines such as GM-CSF, leukemia inhibitory factor,
and IL-6 (7). Thus, IL-17 appears to provide a direct link-
age between T cell activation and inflammatory responses.
Indeed, IL-17 has been implicated in Th1-mediated in-
flammatory diseases such as rheumatoid arthritis and organ
transplant rejections (7–11).
Like TNF and IL-1, which elicit similar cellular re-
sponses, IL-17 also activates the transcription factors nu-
clear factor (NF)-
 
k
 
B and activator protein (AP)-1, impor-
tant mediators of gene regulatory activities exhibited by
proinflammatory cytokines (6, 12–14). AP-1 is activated by
a phosphorylation event mediated by mitogen-activated
protein kinases, including c-Jun NH
 
2
 
-terminal kinase
(JNK)-1 (15), whereas NF-
 
k
 
B activation is preceded by the
activation of I
 
k
 
B kinase-
 
a
 
 and -
 
b
 
 (IKKs), which are
present in most cell types as a heterocomplex (16–21). The
IKKs phosphorylate two specific serine residues on the I
 
k
 
B
proteins, marking them for proteolysis (22–26). The degra-
dation of the inhibitory I
 
k
 
B proteins results in the release
and nuclear translocation of the NF-
 
k
 
B proteins, which
transcriptionally activate target genes.
TNF and IL-1 signal through different cell surface recep-
tors and utilize different sets of receptor-proximal signaling
molecules. TNF induces the trimerization of its type I
receptor (the major signaling receptor relative to the type
II receptor), which initiates a signaling cascade engaging
the adapter TRADD (TNF receptor–associated death do-
main protein), the serine/threonine kinase RIP (receptor-
interacting protein), and TNF receptor–associated factor
(TRAF)2 (27–29). IL-1 induces the heterocomplex forma-
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tion of two different receptor chains, the type I receptor
(IL-1R1) and the receptor accessory protein (IL-1RAcp)
(30–32). This triggers the signaling events that involve the
adapter molecule MyD88, the serine/threonine kinase
IRAK (IL-1 receptor–associated kinase), and TRAF6 (33–
35). TRAF2 and TRAF6 mediate the activation of both
IKK and JNK (36). Therefore, the TRAF proteins repre-
sent a class of adapters that lead distinct upstream signaling
pathways for different cytokines to a point of convergence.
The receptor of IL-17 (IL-17R) is a type 1 transmem-
brane protein with an apparent molecular mass of 130 kD
(37). It does not share sequence homology with the recep-
tors of TNF, IL-1, or other cytokines. Little is known
about the molecular signaling mechanism of IL-17R. In
this study, we used TRAF2- and TRAF6-deficient mouse
embryonic fibroblasts (MEFs) to study the role of TRAF
molecules in IL-17–induced NF-
 
k
 
B and JNK activation.
Our results indicate that TRAF6 is a critical signaling mol-
ecule in the IL-17 signaling pathway.
 
Materials and Methods
 
Cell Culture and Biological Material.
 
Primary EFs were gifts
from T.W. Mak’s laboratory (Amgen Institute/Ontario Cancer
Institute, Toronto, Ontario, Canada). The cells were derived
from embryos at day 14.5 of gestation as described previously
(38, 39). EFs and human embryonic kidney (HEK) 293 cells
were cultured in high glucose DME (Cellgro) supplemented
with 10% certified FBS, 10 mM glutamine, and 50 
 
m
 
g/ml each
of streptomycin and penicillin (GIBCO BRL) in a humidified
incubator with 5% CO
 
2
 
. Mouse TNF was provided by Genen-
tech; human IL-1
 
b
 
 and mouse IL-17 were purchased from Bio-
source.
 
Luciferase Reporter Assays.
 
To reconstitute IL-17 response,
TRAF6
 
1
 
/
 
2
 
 and TRAF6
 
2
 
/
 
2
 
 MEFs were seeded in six-well (35
mm) plates and transfected on the following day with 0.5 
 
m
 
g of
luciferase reporter gene controlled by a basic promoter and six
NF-
 
k
 
B binding sites, 2 
 
m
 
g of pRSV-
 
b
 
-gal, and 50 ng of either
vector DNA or TRAF6 expression plasmid DNA (34) using the
Effectene Transfection Reagent (QIAGEN Inc.) according to
manufacturer-recommended protocol. 36 h after transfection,
the cells were stimulated with TNF (25 g/ml) or IL-17 (100
g/ml) for 8 h. Luciferase activity and 
 
b
 
-galactosidase activity was
determined with the Luciferase Assay System (Promega Corp.)
and chemiluminescent reagents from Tropix, respectively.
 
Electrophoretic Mobility Assay.
 
To assay NF-
 
k
 
B–DNA binding
activity, 2 
 
3 
 
10
 
5
 
 EFs were seeded in 3.5-cm dishes for 24 h. The
cells were cultured in serum-free medium for 1 h before the ad-
dition of cytokines. At indicated times (see Fig. 1) after cytokine
induction, the cells were harvested with PBS containing 1 mM
EDTA. Nuclear extract preparation and gel electrophoretic mo-
bility shift assay (EMSA) were performed as described previously
(40).
 
In Vitro Kinase Assay and Immunoblotting Analysis.
 
EFs (10
 
6
 
)
were either left untreated or were treated with the indicated cy-
tokines (see Fig. 2) for 10 min in the absence of serum. Cells
were rinsed with cold PBS and lysed on ice for 20 min in lysis
buffer (50 mM Hepes, pH 7.6; 125 mM NaCl; 1.5 mM MgCl
 
2
 
;
10% glycerol; 0.5% NP-40; 1 mM EGTA; protease inhibitor
cocktail [Boehringer Mannheim]; 20 mM 
 
b
 
-glycerophosphate; 1
mM sodium orthovanadate; and 5 mM 
 
p
 
-nitro-phenylphos-
 
phate). Cell debris was pelleted by centrifugation at 14,000 rpm
for 20 min. IKK–NEMO (NF-
 
k
 
B essential modulator) protein
complex in the supernatants was immunoprecipitated using anti-
NEMO rabbit antiserum and assayed for activity that phosphory-
lated recombinant I
 
k
 
B-
 
a
 
 (amino acids 1–250) as previously de-
scribed (40). JNK was precipitated with anti–JNK-1 mAb
(PharMingen), and the kinase activity was detected in an in vitro
kinase assay using recombinant GST–c-Jun 1-79 fusion protein
as a substrate (Santa Cruz Biotechnology).
To detect IKK-
 
a
 
 and IKK-
 
b
 
 immunoprecipitated with anti-
NEMO antiserum, the immunoprecipitates were separated by
10% SDS-PAGE, transferred to nitrocellulose membrane, and
immunoblotted with anti–IKK-
 
a
 
 and anti–IKK-
 
b
 
 polyclonal
antibodies (Santa Cruz Biotechnology) as described earlier (40).
JNK-1 was detected with an anti–JNK-1 rabbit polyclonal anti-
body (Santa Cruz Biotechnology).
 
Expression Plasmids, Transfection, and Coimmunoprecipitation.
 
Expression plasmids for Flag-tagged CD40 and Flag-tagged IL-
1R1 were described elsewhere (33, 41). Mammalian expression
plasmid for Flag-tagged IL-17R was constructed by inserting
PCR-generated cDNA lacking the coding sequence for the sig-
nal peptide into expression vector pFlag-CMV-1 (Eastman
Kodak Co.). For coprecipitation experiments, 2 
 
3
 
 10
 
6
 
 HEK 293
cells were plated on 10-cm dishes and transfected the following
day with indicated amounts of expression constructs (see Fig. 5).
After 18 h, the cells were collected, washed once with PBS, and
lysed for 20 min on ice with lysis buffer. Cell lysates were incu-
bated for 2 h with anti-Flag M2 beads (Sigma Chemical Co.). Af-
ter extensive washing with lysis buffer, the beads were eluted
with 400 
 
m
 
M Flag peptide (Sigma Chemical Co.), separated by
SDS-PAGE, and transferred to nitrocellulose membrane. Immu-
noblot analysis was performed with an anti-Myc or anti-HA
(hemagglutinin) mAb (Babco). Expression of transfected con-
structs was verified by immunoblotting aliquot of cell lysates.
 
Determination of IL-6 Secreted by MEFs.
 
EFs were seeded at a
density of 3 
 
3
 
 10
 
4
 
 cells per well in 24-well plates and cultured
for 24 h. Cells were left untreated or stimulated with TNF, IL-1,
or IL-17 for 15 h. IL-6 concentration of the culture supernatant
was determined by ELISA (Endogen) using manufacturer’s pro-
tocols.
 
Immunostaining of Cell Surface IL-17R and ICAM-1.
 
To de-
tect IL-17R, EFs (5 
 
3 
 
10
 
5
 
) were first incubated for 1 h with PBS
containing goat anti–murine (m)IL-17R antiserum (Santa Cruz
Biotechnology) or control serum. After washing twice with PBS,
the cells were incubated for 1 h with FITC-conjugated antibod-
ies to goat IgG (Santa Cruz Biotechnology). Flow cytometry was
performed using a FACSCalibur™ Analyzer (Becton Dickin-
son). For detection of ICAM-1, cells were treated for 15 h with
10 ng/ml of TNF, IL-1, or IL-17 or were left untreated. The
cells were first incubated with mAb to ICAM-1 (PharMingen)
and then stained with FITC-conjugated antibodies to mouse IgG
(Santa Cruz Biotechnology).
 
Results and Discussion
 
Impairment of IL-17–induced NF-
 
k
 
B Activation in TRAF6-
deficient Cells.
 
EFs obtained from TRAF6
 
2
 
/
 
2
 
 embryos or
their wild-type littermates were stimulated with IL-17,
TNF, or IL-1. NF-
 
k
 
B–DNA binding activity was exam-
ined by EMSA. In wild-type cells, NF-
 
k
 
B activation was
detected 10 min after IL-17 treatment, followed by a con-
tinued increase up to 40 min (Fig. 1 A). Similar results 
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were obtained with heterozygous EF cells (TRAF6
 
1
 
/
 
2
 
;
data not shown). However, in TRAF6
 
2
 
/
 
2
 
 cells, no NF-
 
k
 
B activation was detected within the time frame exam-
ined. In agreement with a previous report, TRAF6
 
2
 
/
 
2
 
cells also failed to respond to IL-1 (38). In contrast, TNF-
induced NF-
 
k
 
B activation was unaltered by TRAF6 gene
disruption, indicating that TRAF6 deficiency only causes
defect in response to specific cytokines.
Because TRAF2 has been also implicated in NF-
 
k
 
B ac-
tivation by certain cytokines (39, 42–44), we examined if
IL-17–induced NF-
 
k
 
B activation was affected by TRAF2
deficiency. Treatment of TRAF2
 
2
 
/
 
2
 
 MEFs with either IL-
17 or IL-1 induced NF-
 
k
 
B activity comparable to that ob-
served in the wild-type control cells (Fig. 1 B), whereas
NF-
 
k
 
B activation induced by 20 min of TNF treatment
was significantly reduced. These results indicate that
TRAF2 is involved in signal transduction of TNF, as de-
scribed previously (39), but not in that of IL-1 or IL-17.
 
Abolishment of IL-17–induced IKK Activation in TRAF6-
deficient Cells.
 
NF-
 
k
 
B activation induced by IL-1, TNF,
and LPS entails the activation of IKKs. We investigated
whether IL-17–induced NF-
 
k
 
B activation is also mediated
by the IKKs, and if so, whether IL-17–induced IKK activa-
tion is impaired in the TRAF6 knockout cells. IKK com-
plex in TRAF6
 
1
 
/
 
2
 
 or TRAF6
 
2
 
/
 
2 
 
EFs untreated or treated
with TNF, IL-1, or IL-17 was coimmunoprecipitated with
antibodies against NEMO, a stable component in the IKK
complex (17, 19). Immunoblot analysis indicated that simi-
lar amounts of IKK-
 
a
 
 and -
 
b
 
 were immunoprecipitated from
untreated or cytokine-treated TRAF6
 
1
 
/
 
2
 
 and TRAF6
 
2
 
/
 
2
 
cells (Fig. 2). The immunoprecipitates were then assayed
for activity to phosphorylate recombinant I
 
k
 
B-
 
a
 
 (amino
acids 1–250) containing IKK substrate, serines 32 and 36.
Figure 1. NF-kB activation in MEFs. (A) Lack of NF-kB activation in
TRAF6-deficient cells in response to IL-1 and IL-17. Nuclear extracts
were prepared from TRAF61/1 or TRAF62/2 MEFs treated for indi-
cated length of time with 25 ng/ml mTNF, 50 ng/ml IL-1, or 100 ng/ml
mIL-17. 6 mg of protein from each sample was tested for ability to bind to
a synthetic DNA fragment containing an NF-kB binding site in an
EMSA. (B) Normal NF-kB activation in TRAF2-deficient cells in re-
sponse to IL-17. The same experiments as in A were performed with
MEFs derived from TRAF2-deficient mouse embryos and their wild-
type littermates.
Figure 2. Kinase activity of the IKK complex and JNK isolated from
TRAF6-deficient MEFs. (A) TRAF6-deficient (2/2) and heterozygous
EFs (1/2) were treated with 25 ng/ml mTNF, 50 ng/ml IL-1, or 100
ng/ml mIL-17 for 10 min. The IKK complex was immunoprecipitated
using anti-NEMO polyclonal antibodies and assayed for activity to phos-
phorylate IkB-a (amino acids 1–250) (top panel [KA], in vitro kinase as-
say). Immunoprecipitated materials were separated by SDS-PAGE and
immunoblotted with a mixture of antibodies to IKK-a and IKK-b (bot-
tom panel [IB], immunoblot). Molecular mass standards are shown in ki-
lodaltons. (B) JNK-1 was precipitated from wild-type, TRAF2-deficient,
and TRAF6-deficient MEFs treated with indicated cytokines and assayed
for their activity to phosphorylate recombinant c-Jun (top panel). The
amounts of precipitated JNK-1 were determined by immunoblotting
(bottom panel). 
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Treatment of TRAF6
 
1
 
/
 
2
 
 cells with TNF, IL-1, or IL-17
significantly enhanced the IKK activity, as evidenced by
increased phosphorylation of I
 
k
 
B-
 
a
 
, NEMO, and IKKs
(Fig. 2 A). On the other hand, IKK activity in the
TRAF6
 
2
 
/
 
2
 
 cells was enhanced only by TNF and not by
IL-1 or IL-17. These results indicate that, like TNF and
IL-1, IL-17 activates NF-kB by inducing the catalytic ac-
tivity of the IKKs, and that IL-17–induced IKK activation
involves TRAF6.
Similar results were obtained when JNK activity was
measured in TRAF-deficient cells (Fig. 2 B). IL-17– and
IL-1–induced JNK activation was abolished in TRAF6
knockout cells but remained intact in TRAF2 knockout
cells. In agreement with an earlier report (39), a reduction
of TNF-induced JNK activation was observed in TRAF2-
deficient cells.
Failure of IL-17 to Induce IL-6 and ICAM-1 Expression in
TRAF6-deficient Cells. To examine if the failure of IL-17
to activate IKK and NF-kB would be translated to its in-
ability to activate target genes, we measured IL-6 secretion
by TRAF6-deficient MEFs. Control MEFs responded to
TNF, IL-1, and IL-17 with a significant increase in IL-6
secretion (Fig. 3 A). The TRAF6 knockout cells, on the
other hand, failed to produce increased levels of IL-6 in re-
sponse to either IL-17 or IL-1. An increase of IL-6 secre-
tion by the TRAF6-deficient cells was observed after TNF
treatment, albeit at a slightly lower level relative to that se-
creted by control cells. Because TNF induces the release of
IL-1, which could contribute to the net increase of IL-6 se-
cretion by TNF-treated cells, this slight reduction in TNF
response may be due to a defect in IL-1 response observed
in the TRAF62/2 cells.
Similar results were obtained when ICAM-1 cell surface
expression was measured by flow cytometry. All three cy-
tokines induced ICAM-1 expression on wild-type MEFs,
with the strongest induction observed after TNF treatment
(Fig. 3 B). Although TNF-induced increase in ICAM-1
expression remained intact in TRAF62/2 cells, the effects
of IL-1 and IL-17 were diminished. These results further
support that IL-17–induced response gene activation is me-
diated by NF-kB and that TRAF-6 is indispensable for the
gene regulatory activities of IL-17.
Figure 3. Target gene activation in TRAF6-deficient MEFs. (A) Fail-
ure of IL-17 to increase IL-6 production by the TRAF6-deficient EFs.
Wild-type (1/1) or TRAF6-deficient (2/2) EFs were cultured in the
presence of 10 ng/ml mTNF, 10 ng/ml IL-1, or 10 ng/ml mIL-17 for
15 h. IL-6 in cell culture medium was determined by ELISA. Data shown
are average values of three independent experiments 6 SD. (B) Failure of
IL-17 to increase ICAM-1 expression on TRAF6-deficient cells. Wild-
type or TRAF62/2 cells were treated with cytokines as in A. Levels of
ICAM-1 protein on cell surface were determined by FACS® analysis us-
ing mouse mAbs specific to ICAM-1. Dotted line, untreated cells; solid
line, cytokine-treated cells.
Figure 4. Surface Expression of IL-17R on MEFs and restoration of
IL-17 response by transient introduction of TRAF6 protein into
TRAF62/2 cells. (A) Determination of IL-17R on TRAF61/2 and
TRAF62/2 MEFs by FACS® analysis using polyclonal antibody to mouse
IL-17R. Dotted line, mouse-matched isotype IgG; solid line, anti–IL-
17R. (B) Reconstitution of IL-17 response. Wild-type or TRAF6-defi-
cient EFs were transfected with RSV-b-gal vector, an NF-kB–dependent
luciferase reporter construct, together with 50 ng of vector DNA or
TRAF6 expression plasmid. Cells were left untreated (open bars) or stim-
ulated with 25 ng/ml TNF (closed bars) or 100 ng/ml IL-17 (hatched
bars) for 8 h. Luciferase activity was determined and normalized based on
b-gal activity.1237 Schwandner et al. Brief Definitive Report
Determinative Effect of TRAF6 Deficiency in IL-17 Re-
sponse. To exclude the possibility that the observed unre-
sponsiveness to IL-17 in TRAF62/2 cells might be due to
insufficient surface expression of IL-17R, EFs were immu-
nostained with an antiserum against mouse IL-17R and an-
alyzed by flow cytometry. The results indicate that
TRAF61/2 and TRAF62/2 cells expressed similar levels of
IL-17R (Fig. 4 A).
To further eliminate the possibility that failure of
TRAF62/2 cells to respond to IL-17 could be caused by
defects other than TRAF6 deficiency, we tested if IL-17–
induced NF-kB activation could be restored by introduc-
ing exogenous TRAF6 into these cells. TRAF62/2 cells
were transiently transfected with an NF-kB–driven lu-
ciferase report construct together with a TRAF6 expres-
sion plasmid or a control vector. Mirroring NF-kB activity
measured by EMSA (Fig. 1), IL-17 failed to induce lu-
ciferase activity in TRAF62/2 cells, although response to
TNF appeared normal (Fig 4 B). TRAF62/2 cells trans-
fected with TRAF6 expression plasmid responded to IL-17
with an increase of luciferase activity similar to that ob-
served in control cells.
Binding of TRAF6 to IL-17R. Previous studies indi-
cate that TRAF6 can be recruited to signaling pathways in
two modes. It can either bind directly to the receptor intra-
cellular domain, as in the signaling of CD40 and receptor
activator of NF-kB (38, 45–47), or be recruited into the
pathways by adapter proteins, as in the signaling of IL-1,
IL-18, and LPS (48, 49). To determine if TRAF6 interacts
with IL-17R, we coexpressed Flag-tagged IL-17R, IL-
1R1, or CD40 together with Myc-tagged TRAF6 in 293
cells. In agreement with our earlier finding, TRAF6 did
not coimmunoprecipitate with IL-1R1 (34). In contrast,
TRAF6 coimmunoprecipitated with IL-17R or CD40
(Fig. 5). To determine if this IL-17R–TRAF6 interaction
is specific to TRAF6, the same set of Flag-tagged receptors
was also coexpressed with HA-tagged TRAF2. TRAF2
was found in the immunoprecipitates of CD40, in agree-
ment with previous reports (47, 50), but was not detected
in the IL-17R complex. These observations further support
the involvement of TRAF6, but not TRAF2, in IL-17 sig-
naling. Because similar amounts of TRAF6 were detected
in IL-17R and CD40 complex, TRAF6 may bind to IL-
17R directly, although we cannot rule out a remote possi-
bility that this interaction might be mediated by an abun-
dant adapter molecule. The nature of the TRAF6 and
IL-17R interaction will be addressed in detail when good
antibodies to IL-17R become available.
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helpful discussion; Mark Lomaga, Wen-Chen Yeh, and Tak W.
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